Online inquiry

IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4569MR)

This product GTTS-WQ4569MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CXCR4 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001008540.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7852
UniProt ID P61073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4569MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14993MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ9127MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ10455MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ5836MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ4432MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ6418MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ8909MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ14356MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW